AU9402898A - Cell death agonists - Google Patents

Cell death agonists

Info

Publication number
AU9402898A
AU9402898A AU94028/98A AU9402898A AU9402898A AU 9402898 A AU9402898 A AU 9402898A AU 94028/98 A AU94028/98 A AU 94028/98A AU 9402898 A AU9402898 A AU 9402898A AU 9402898 A AU9402898 A AU 9402898A
Authority
AU
Australia
Prior art keywords
cell death
death agonists
agonists
cell
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU94028/98A
Other languages
English (en)
Inventor
Stanley J Korsmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU9402898A publication Critical patent/AU9402898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU94028/98A 1997-09-26 1998-09-22 Cell death agonists Abandoned AU9402898A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6013397P 1997-09-26 1997-09-26
US60060133 1997-09-26
US94603997A 1997-10-07 1997-10-07
US08946039 1997-10-07
PCT/US1998/019765 WO1999016787A1 (fr) 1997-09-26 1998-09-22 Agonistes de mort cellulaire

Publications (1)

Publication Number Publication Date
AU9402898A true AU9402898A (en) 1999-04-23

Family

ID=26739603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU94028/98A Abandoned AU9402898A (en) 1997-09-26 1998-09-22 Cell death agonists

Country Status (2)

Country Link
AU (1) AU9402898A (fr)
WO (1) WO1999016787A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221615B1 (en) 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6165732A (en) * 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6190912B1 (en) * 1998-03-31 2001-02-20 Thomas Jefferson University Blk genes and uses thereof in apoptosis
AU5761200A (en) * 1999-06-25 2001-01-31 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Bh3 modified peptides
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2005507636A (ja) 2000-12-22 2005-03-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 酵母及び真菌における薬物標的同定のためのｂａｘ応答遺伝子
EP1611153B1 (fr) * 2003-04-02 2010-06-16 Board Of Regents, The University Of Texas System Effet antitumoral d'un mutant du bik
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드
EP1737966B1 (fr) 2004-04-02 2012-05-09 Board of Regents, The University of Texas System Promoteurs specifiques du cancer
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2007035494A2 (fr) * 2005-09-16 2007-03-29 The Regents Of The University Of California Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite
WO2008152405A2 (fr) * 2007-06-15 2008-12-18 The Queen's University Of Belfast Cible anti-cancer
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2013192423A2 (fr) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles pour traiter les maladies impliquant des protéines de la famille bcl-2 avec des dérivés de quinoline
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
CA2903275A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques permeables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
PL222795B1 (pl) * 2013-12-22 2016-09-30 Univ Warszawski Rekombinowane białko fuzyjne ProSTAT do zastosowania w leczeniu
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
RU2717829C2 (ru) 2015-04-20 2020-03-26 Толеро Фармасьютикалз, Инк. Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (fr) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Peptides de profilage et procedes de profilage de sensibilite
WO2019055579A1 (fr) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN113549143B (zh) * 2021-07-21 2022-05-27 吉林大学 一种抗肿瘤多肽Bax-BH3、荧光高分子纳米胶束及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis

Also Published As

Publication number Publication date
WO1999016787A9 (fr) 1999-06-24
WO1999016787A1 (fr) 1999-04-08

Similar Documents

Publication Publication Date Title
AU9402898A (en) Cell death agonists
EP0882553B8 (fr) Couteau
AU5998598A (en) Electrochemical cell
AU1268899A (en) Microstrip arrangement
AU1407699A (en) Distributed architecture utility
AU1709299A (en) Mixer-injectors
AU5566598A (en) Hydrogels
AU1725099A (en) Devices for cloaking transplanted cells
AU2548699A (en) Cell death inhibitors
AU7349298A (en) Prostaglandin agonists
AU1027499A (en) 32P-polyphosphazene
AU6345498A (en) Antisense compounds which prevent cell death and uses thereof
AU5185899A (en) Pack
AU8180298A (en) Utility knife
AU8979698A (en) Solutions containing azasteroids
AU6036099A (en) Battery holder
AU4117497A (en) Micropolarimeter
AU9732098A (en) Hematopoietic stem cells
AU5185799A (en) Pack
AU8243798A (en) Agm-derived stroma cells
AU6634298A (en) Biosensor for cells
AU1505999A (en) Immunosuppressant agonists
AU1913299A (en) Battery cathode
AU9649198A (en) Enclosed cell
AU4469997A (en) Heregulin-gamma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase